The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responsesFang Chen, Jim Xiang, Scot C. Leary et al.|Frontiers in Immunology|2025Cited by 0